처방약 시장 규모, 점유율, 성장률 및 세계 업계 분석 : 유형 및 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of prescription drugs Market

The global prescription drugs market was valued at USD 1,324.44 billion in 2025 and is projected to grow to USD 1,415.52 billion in 2026, eventually reaching USD 2,492.84 billion by 2034, reflecting a robust CAGR of 7.33% during the forecast period. North America dominated the market in 2025 with a 49.66% share, primarily driven by high healthcare expenditure, advanced therapies, and the presence of major pharmaceutical companies focusing on generic and specialty medicines. The U.S. prescription drugs market alone is expected to reach USD 931.1 million by 2032, fueled by the increasing approval of orphan drugs and rising demand for specialty medications.

Prescription drugs encompass vaccines, biologics, and therapies used to manage both chronic and acute diseases such as cancer, cardiovascular disorders, diabetes, and rare (orphan) diseases. The market has witnessed significant changes in recent years, including an influx of generic equivalents, impacting overall adoption and accessibility. The COVID-19 pandemic caused a temporary decline in 2020 due to lockdowns, restricted hospital visits, and disruptions in supply chains, leading to shortages and reduced drug expenditures globally. According to the American Society of Health-System Pharmacists, prescription drug spending in nonfederal hospitals fell by 4.6% in 2020. However, the resurgence of routine healthcare services, increased patient visits, and rising R&D initiatives, particularly for COVID-19 treatments, contributed to renewed growth in the market.

Market Trends

Pipeline Expansion Across Therapy Areas

Increasing R&D investments by pharmaceutical companies are a critical trend in the market. In Europe, research-based pharmaceutical companies invested approximately USD 43,684.2 million in R&D in 2021 to develop drugs addressing chronic disorders. Companies are increasingly focusing on rare diseases (orphan drugs), with numerous clinical trials ongoing, which is expected to fuel market growth over the forecast period.

Generic Drug Adoption

The launch of generic equivalents is a key growth driver. In October 2019, the U.S. FDA approved 1,171 generic drugs, enhancing competition and making medications more affordable. Government initiatives, such as India's Aushadhi Scheme, offer generic drugs at 50-90% lower costs, further supporting market expansion.

Orphan Drugs Development

The increasing focus on orphan drugs is another major factor. Companies such as BioMarin and Baudax Bio are developing therapies for rare diseases, with orphan drug approvals enabling accelerated clinical trials and eventual market entry, creating opportunities for blockbuster drugs in previously underserved markets.

Market Restraints

Despite the growth drivers, high costs associated with prescription drugs limit market penetration. Developing a new drug can cost USD 2.6 billion, and certain therapies, such as Abiraterone for prostate cancer, may cost USD 10,000 per month, making affordability a challenge, particularly in developing regions.

Market Segmentation

By Product Type

• Other Prescription Drugs dominate, accounting for 71.71% globally in 2026, driven by oncology, anti-diabetic, and cardiovascular medications without immediate generic equivalents.
• Orphan drugs are expected to grow at a higher CAGR, supported by increasing clinical trials and regulatory approvals.
• Generics benefit from affordability and increasing adoption in emerging markets.

By Therapy

• Oncology leads, representing 67.55% globally in 2026, due to high cancer prevalence and targeted therapy approvals.
• Other segments include central nervous system drugs, vaccines, immunosuppressants, and others, all showing growth driven by rising disease prevalence and regulatory approvals.

By Distribution Channel

• Hospital pharmacies dominate, as critical medications often require professional administration.
• Retail pharmacies and online pharmacies are growing, with online pharmacies expected to register the highest CAGR due to convenience in prescription refills.

Regional Insights

• North America: Market size of USD 657.68 billion in 2025, projected to USD 703.04 billion in 2026, led by advanced therapies and high healthcare expenditure. The U.S. is expected to reach USD 607.6 billion in 2026.
• Europe: Accounted for USD 271.21 billion in 2025, projected to USD 288.77 billion in 2026, driven by generic launches and orphan drugs.
• Asia Pacific: Strong presence at USD 300.57 billion in 2025, projected to USD 323.5 billion in 2026, with Japan, China, and India being key contributors.
• Latin America & Middle East & Africa: Represent USD 61.64 billion and USD 33.33 billion respectively in 2025, with steady growth expected through 2034.

Key Companies & Developments

Major players include Novartis AG, Pfizer, Roche, Sanofi, Johnson & Johnson, Merck, AbbVie, GlaxoSmithKline, and AstraZeneca, alongside generic-focused companies like Dr Reddy's Laboratories and Lupin Pharmaceuticals. Recent developments include:

• October 2023: Novartis spun off Sandoz to focus on innovative medicines.
• January 2023: Amgen launched biosimilar AMJEVITA in the U.S.
• 2020-2022: Multiple launches of generic and specialty drugs by Lupin and Dr. Reddy's in the U.S.

Conclusion

The global prescription drugs market is on a sustained growth trajectory from USD 1,324.44 billion in 2025 to USD 2,492.84 billion in 2034, driven by chronic and rare disease prevalence, increased R&D, generic drug adoption, and rising specialty medication approvals. While high costs may restrain some adoption, regional government initiatives, pipeline expansion, and innovations in hospital and homecare therapies ensure robust market expansion. North America remains the dominant market, with Asia Pacific emerging as a high-growth region due to expanding healthcare infrastructure and rising awareness of chronic diseases.

Segmentation By Product Type

• Generics
• Orphan
• Other Prescription Drugs

By Application

• Oncology
• Central Nervous System
• Vaccines
• Immunosuppressants
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Others

By Geography

• North America (By Product Type, By Application, By Distribution Channel, and By Country)
  • U.S.
  • Canada
• Europe (By Product Type, By Diabetes Type, By Distribution Channel, and By Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases - By Key Countries/ Region, 2026
• 4.2. Pipeline Analysis, By Key Players
• 4.3. Key Industry Developments, By Key Players
• 4.4. Regulatory Scenario, By Key Regions
• 4.5. New Product Launches, By Key Players
• 4.6. Impact of COVID-19 on the Market

5. Global Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Generics
  • 5.1.2. Orphan
  • 5.1.3. Other Prescription Drugs
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Oncology
  • 5.2.2. Central Nervous System
  • 5.2.3. Vaccines
  • 5.2.4. Immunosuppressants
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Retail Pharmacies & Drug Stores
  • 5.3.3. Online Pharmacies
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Generics
  • 6.1.2. Orphan
  • 6.1.3. Other Prescription Drugs
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Oncology
  • 6.2.2. Central Nervous System
  • 6.2.3. Vaccines
  • 6.2.4. Immunosuppressants
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Retail Pharmacies & Drug Stores
  • 6.3.3. Online Pharmacies
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Generics
  • 7.1.2. Orphan
  • 7.1.3. Other Prescription Drugs
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Oncology
  • 7.2.2. Central Nervous System
  • 7.2.3. Vaccines
  • 7.2.4. Immunosuppressants
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacies & Drug Stores
  • 7.3.3. Online Pharmacies
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Rest of Europe

8. Asia Pacific Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Generics
  • 8.1.2. Orphan
  • 8.1.3. Other Prescription Drugs
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Oncology
  • 8.2.2. Central Nervous System
  • 8.2.3. Vaccines
  • 8.2.4. Immunosuppressants
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies & Drug Stores
  • 8.3.3. Online Pharmacies
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Generics
  • 9.1.2. Orphan
  • 9.1.3. Other Prescription Drugs
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Oncology
  • 9.2.2. Central Nervous System
  • 9.2.3. Vaccines
  • 9.2.4. Immunosuppressants
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail Pharmacies & Drug Stores
  • 9.3.3. Online Pharmacies
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Generics
  • 10.1.2. Orphan
  • 10.1.3. Other Prescription Drugs
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Oncology
  • 10.2.2. Central Nervous System
  • 10.2.3. Vaccines
  • 10.2.4. Immunosuppressants
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies & Drug Stores
  • 10.3.3. Online Pharmacies
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2026)
• 11.2. Company Profiles
  • 11.2.1. Novartis AG
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Pfizer, Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. F. Hoffmann-La Roche Ltd.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Sanofi
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Johnson & Johnson Services, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Merck & Co., Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. AbbVie, Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. GlaxoSmithKline plc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. AstraZeneca
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. CELGENE CORPORATION (BRISTOL-MYERS SQUIBB COMPANY)
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)